Monitoring of antiplatelet drug effects--fashion or necessity?
Kuliczkowski, W.; Zembala, M.; Poloński, L.; Kaczmarski, J.; Gasior, M.
Kardiologia Polska 66(1): 119-124
2008
ISSN/ISBN: 0022-9032 PMID: 18266199 Document Number: 622132
Document emailed within 1 workday
Related Documents
Zoppi, M.; Török, M.; Stoller-Güleryüz, D.; Winzenried, P.; Marty, H.; Hess, T.; Stucki, P.; Bickel, M.H.; Stocker, F.; Hoigné, R. 1982: Drug side effects as the probable cause of death. Results of the Berne Comprehensive Hospital Drug Monitoring Program Schweizerische Medizinische Wochenschrift 112(49): 1808-1810Matsuda, T. 1993: Antithrombotic drug (thrombolytic drug, anticoagulant, antiplatelet drug) Nihon Rinsho. Japanese Journal of Clinical Medicine 51 Suppl: 179-185
Jaźwińska-Tarnawska, E.; Wiela-Hojeńska, A.; Wolańczyk-Medrala, A.; Patkowski, J.; Nittner-Marszalska, M.; Głowacka, K. 2012: Monitoring of NSAIDs adverse effects based on spontaneous reports from Wrocław regional adverse drug reactions monitoring center Acta Poloniae Pharmaceutica 69(5): 979-984
Siest, G.; Delwaide, P.; Malya, P.A.G.; Breuer, H.; Galteau, M.M.; Salway, J.G.; Tognoni, G.; Tryding, N. 1988: International Federation of Clinical Chemistry, Scientific Committee: Drug interferences and drug effects in clinical chemistry. Part 6. Laboratory tests in monitoring drug administration Journal of Clinical Chemistry and Clinical Biochemistry 26(3): 181-186
Sørensen, T.L.; Johansen, H.L.; Ingvardsen, B.K.; Larsen, L. 1998: The microbial threat 3. Monitoring of the utilization of antibiotics--a necessity! Ugeskrift for Laeger 160(44): 6336-6339
Yang, Y-Yin.; Dong, Z.; Xia, Y-Peng. 2012: Discussion on adverse reactions monitoring modes of drug manufacturers under new measures for administration of adverse drug reaction report and monitoring Zhongguo Zhong Yao Za Zhi 37(21): 3329-3333
Ahmad, S. 1984: Drug interactions complicate antiplatelet therapy Geriatrics 39(5): 137
Ikeda, Y. 1992: Pharmacological aspects of a novel antiplatelet drug, E5510 Nihon Rinsho. Japanese Journal of Clinical Medicine 50(2): 366-371
Tsvetaeva, N.V.; Sokolova, M.A.; Semenova, E.A.; Kolodeĭ, S.V.; Vasil'ev, S.A.; Orel, E.B.; Vadinskaia, L.A.; Khoroshko, N.D. 2002: A new antiplatelet drug agrilin in treating patients with hyperthrombocytosis Terapevticheskii Arkhiv 74(8): 72-74
Segarra Domenech, J. 1988: Necessity for rational drug therapy Revista Clinica Espanola 183(9): 495-499
Jabłecka, A.; Jankowski, J.; Andrys, I. 2000: The system of drug side effects monitoring in the cardiological wards of the University Hospital No. 1 in Poznań. 6-year observation Wiadomosci Lekarskie 53(5-6): 277-282
Guha, S.; Sardar, P.; Guha, P.; Roy, S.; Mookerjee, S.; Chakrabarti, P.; Deb, P.K.; Chaudhuri, U.; Deb, S.; Karmakar, R.; Dasgupta, A.K.; Lahiri, P. 2009: Dual antiplatelet drug resistance in patients with acute coronary syndrome Indian Heart Journal 61(1): 68-73
Lavarenne, J.; Dumas, R.; Cayrol, C. 1983: Adverse effects of drugs in old people. Evaluation of cases received for a year at the French Association of Drug Monitoring Centers Therapie 38(5): 485-493
Wang, D.; Du, X-Xi. 2012: Interpretation of adverse drug reaction reporting and monitoring and significance of traditional Chinese medicine adverse drug reaction monitoring Zhongguo Zhong Yao Za Zhi 37(18): 2686-2688
Zaka-Ur-Rehman, Z.; Jamshaid, M.; Chaudhry, A. 2008: Clinical evaluation and monitoring of adverse effects for fixed multidose combination against single drug therapy in pulmonary tuberculosis patients Pakistan Journal of Pharmaceutical Sciences 21(2): 185-194
Nasu, M.; Shikano, K.; Miyamura, K.; Shinpo, H.; Morimoto, T.; Ohi, T.; Shomura, S.; Yamazaki, N.; Yada, I.; Kusagawa, M. 1983: Evaluation of antiplatelet drug therapy and replaced heart valves based on platelet functions Kyobu Geka. Japanese Journal of Thoracic Surgery 36(9): 701-705
Zoja, C.; Perico, N.; Remuzzi, G. 1991: Antiplatelet agents: effects on the progressive renal disease American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation 17(5 Suppl 1: 98-102
Mazurov, A.V.; Pevzner, D.V.; Vlasik, T.N.; Ruda, M.I. 2004: Antiplatelet effects of glycoproteins IIb-IIIa antagonist monafram Rossiiskii Fiziologicheskii Zhurnal Imeni I.M. Sechenova 90(5): 586-599
Hemmer, J.; Kreidler, J.; Kraft, K.; Schön, E. 1994: Monitoring of anticancer drug effects in vivo by serial DNA flow cytometry of oral carcinomas treated by intra-arterial 5-fluorouracil/cisplatin induction chemotherapy Anticancer Research 14(5b): 2077-2083
Ciorciaro, C.; Hartmann, K.; Stoller, R.; Kuhn, M. 1996: Liver injury caused by coumarin anticoagulants: experience of the IKS (Intercanton Monitoring Station) and the SANZ (Swiss Center for Drug Monitoring) Schweizerische Medizinische Wochenschrift 126(49): 2109-2113